Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.

Juana Carretero GómezJavier EnaJose M Seguí RipollFrancisco J Carrasco-SanchezRicardo Gómez HuelgasLourdes Mateos PoloJosé M Varela AguilarJosé M Suárez TembraJosé Carlos Arévalo-Loridonull null

Published in: International journal of clinical practice (2020)

Our results show the beneficial effect of GLP1ra and SGLT2i combination therapy on early biomarkers of diabetes kidney disease such as albuminuria and in other significant outcomes for diabetes control.

Keyphrases

combination therapy
type diabetes
glycemic control
cardiovascular disease
rheumatoid arthritis
adipose tissue
metabolic syndrome
insulin resistance
skeletal muscle